For personal use only

ASX ANNOUNCEMENT

Lumos Receives Milestone Payment of US$0.5m from BARDA for Achieving FebriDx® CLIA Waiver

MELBOURNE, Australia (7 May 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, "Lumos" or the "Company"), a leader in rapid, point-of-care diagnostic technologies, confirms receipt of the milestone payment of US$507,377, under its contract with the Biomedical Advanced Research and Development Authority (BARDA) for achieving US FDA CLIA waiver for FebriDx®. The receipt of this payment from BARDA brings the total amount received pursuant to the CLIA waiver study to US$2,984,571.

Lumos CEO and Managing Director, Doug Ward commented, *"BARDA's assistance provides not only meaningful non-dilutive funding that extends our capacity to run critical studies, including our paediatric program, but also brings technical expertise as we advance our diagnostic solutions toward broader clinical use."*

This CLIA waiver project was funded in whole or in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50124C00051.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About FebriDx®

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections after 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

Recent CLIA waiver clearance expands the applicability of FebriDx® to over 300,000 locations across the US[1], covering a broad range of healthcare settings, spanning primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres that hold a Certificate of Waiver. This milestone marks a significant commercial achievement for Lumos, positioning FebriDx® to reach tens of millions more patients without the need for complex laboratory infrastructure or specialised training.

With the CLIA waiver now granted, FebriDx® can be deployed more broadly, potentially reaching 80 million patients[2] per annum in the US who present with acute respiratory infections at primary care and

urgent care centres. This unlocks a US$1.0+ billion market opportunity, approximately 15 times larger than the market opportunity available to the Company under the previous moderate-complexity classification.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com, which includes access to the full indications for use.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

1. Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database). 2. Precision Business Insights, US Acute Respiratory Infections, 2024.

For personal use only